Effects of growth hormone on status of children with cystic fibrosis
Phase 1
- Conditions
- Cystic fibrosis with pulmonary manifestations.Cystic fibrosis with pulmonary manifestations
- Registration Number
- IRCT201112275330N3
- Lead Sponsor
- Vice chancellor for research, Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Age under 12 years old; height and weight less than third percentile for age and gender; boyd mass index less than tenth percentile for age and gender.
Exclusion criteria: Having diabetes (fasting glucose equal or less than 126 mg/dl); history of glucocorticoids in last 6 months; appearance of secondary sex characteristics; Cirrhosis of the liver and hypoalbuminemia; oxygen-related lung disorders.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Weight. Timepoint: Before administering growth hormone and after administring growth hormone every 2 months for a period of 6 months. Method of measurement: Using scale.;Height. Timepoint: Before administering growth hormone and after administring growth hormone every 2 months for a period of 6 months. Method of measurement: Using meter.;Times of hospitalization. Timepoint: Before administering growth hormone and after administring growth hormone every 2 months for a period of 6 months. Method of measurement: Questionnaire.;Times of lung infection. Timepoint: Before administering growth hormone and after administring growth hormone every 2 months for a period of 6 months. Method of measurement: Questionnaire.;Times of intravenous antibiotic therapy. Timepoint: Before administering growth hormone and after administring growth hormone every 2 months for a period of 6 months. Method of measurement: Questionnaire.
- Secondary Outcome Measures
Name Time Method